Subscribe To
SRPT / Why Sarepta Therapeutics Stock Faded This Week
SRPT News
By Investors Business Daily
October 31, 2023
Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test
Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results. more_horizontal
By Barrons
October 31, 2023
Sarepta Stock Sinks on Mixed Gene Therapy Results
In a gene therapy study for patients with Duchenne muscular dystrophy, the primary endpoint was not met. more_horizontal
By Investors Business Daily
October 30, 2023
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy
Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted. more_horizontal
By Reuters
October 30, 2023
Sarepta's gene therapy fails to meet primary goal in rare muscular dystrophy trial
Sarepta Therapeutics' gene therapy to treat Duchenne muscular dystrophy failed to reach statistical significance in a late-stage trial, the company re more_horizontal
By The Motley Fool
August 23, 2023
Is Sarepta Therapeutics Stock a Top Growth Vehicle?
Wall Street is expecting big things from the rare disease specialist Sarepta Therapeutics in 2023 and beyond. However, the company does face some impo more_horizontal
By Seeking Alpha
August 2, 2023
Sarepta Therapeutics, Inc. (SRPT) Q2 2023 Earnings Call Transcript
Sarepta Therapeutics, Inc. (NASDAQ:SRPT ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Francesca Nolan - IR Directo more_horizontal
By Zacks Investment Research
August 2, 2023
Sarepta Therapeutics (SRPT) Reports Q2 Loss, Misses Revenue Estimates
Sarepta Therapeutics (SRPT) came out with a quarterly loss of $0.27 per share versus the Zacks Consensus Estimate of a loss of $1.89. This compares to more_horizontal
By Zacks Investment Research
July 25, 2023
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared more_horizontal